2.05
+0.01(+0.49%)
Currency In USD
| Previous Close | 2.04 |
| Open | 2.05 |
| Day High | 2.08 |
| Day Low | 1.97 |
| 52-Week High | 3.29 |
| 52-Week Low | 0.13 |
| Volume | 1.89M |
| Average Volume | 18.04M |
| Market Cap | 259.7M |
| PE | -0.15 |
| EPS | -13.68 |
| Moving Average 50 Days | 1.59 |
| Moving Average 200 Days | 1.06 |
| Change | 0.01 |
If you invested $1000 in Vor Biopharma Inc. (VOR) since IPO date, it would be worth $54.67 as of August 20, 2025 at a share price of $2.05. Whereas If you bought $1000 worth of Vor Biopharma Inc. (VOR) shares 3 years ago, it would be worth $426.2 as of August 20, 2025 at a share price of $2.05.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Aug 18, 2025 8:35 PM GMT
CAMBRIDGE, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, between August 4, 2025, and August 18, 2025, the Compensation
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor
GlobeNewswire Inc.
Aug 13, 2025 12:30 PM GMT
Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept demonstrated a favorable safety profile Vor evaluating timing of global Phase 3 clinical study in primary Sjögren's disease Data anti
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
GlobeNewswire Inc.
Aug 04, 2025 12:30 PM GMT
Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunitiesCAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company t